Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer.

Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dartmouth-Hitchcock Medical Center; Konstantin Dragnev
• Collaborators: Genentech, Inc.; Ligand Pharmaceuticals
• Treatments: Bexarotene; Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Advanced NSCLC

• Prior chemotherapy or radiotherapy is allowed.

Exclusion Criteria:

• Hepatic or renal dysfunction